Marshall Wace’s CapForce IBD 50 ETF FFTY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-11,807
Closed -$328K 2648
2024
Q2
$328K Sell
11,807
-9,635
-45% -$263K ﹤0.01% 2114
2024
Q1
$593K Sell
21,442
-13,164
-38% -$344K ﹤0.01% 1864
2023
Q4
$843K Buy
+34,606
New +$787K ﹤0.01% 1531
2023
Q3
Sell
-15,471
Closed -$396K 2346
2023
Q2
$396K Buy
15,471
+300
+2% +$7.11K ﹤0.01% 2062
2023
Q1
$359K Buy
15,171
+300
+2% +$6.89K ﹤0.01% 2237
2022
Q4
$324K Buy
14,871
+800
+6% +$19.7K ﹤0.01% 2534
2022
Q3
$343K Sell
14,071
-1,000
-7% -$27.7K ﹤0.01% 2895
2022
Q2
$405K Sell
15,071
-1,096
-7% -$35.2K ﹤0.01% 2892
2022
Q1
$632K Buy
16,167
+9,525
+143% +$370K ﹤0.01% 2670
2021
Q4
$305K Buy
+6,642
New +$317K ﹤0.01% 3029

Other funds holding FFTY

Marshall Wace's FFTY Position: Q3 2024 in Review

Marshall Wace sold out of CapForce IBD 50 ETF (FFTY) in Q3 2024, closing a stake of 11,807 shares — an estimated $328K sold.

Marshall Wace first reported a position in FFTY in Q4 2021 and held it in 10 quarters. The position peaked at $843K in Q4 2023. 29 funds tracked by Wall St. Rank hold FFTY as of Q3 2024.

  • Marshall Wace reported no remaining CapForce IBD 50 ETF position as of Q3 2024 after selling out during the quarter.
  • Marshall Wace sold 11,807 CapForce IBD 50 ETF shares in Q3 2024, an estimated $328K.
  • Marshall Wace first reported a position in CapForce IBD 50 ETF in Q4 2021 and held it in 10 quarters.
  • Marshall Wace's CapForce IBD 50 ETF position peaked at $843K in Q4 2023.
  • 29 funds tracked by Wall St. Rank held CapForce IBD 50 ETF as of Q3 2024.

Based on Marshall Wace's 13F filing for Q3 2024, filed 14 Nov 2024.